Nom: Histrelin Acetate
N ° CAS: 76712-82-8 (filet), 220810-26-4 (acétate)
Formule:1323.52
Moléculaire: C66H86N18O12
Pureté:98%
Apparence: poudre blanche
La source: synthétique
Aussi connu sous le nom: Histrelina, Histreline, Histrelinum, Vantaas, Supprelin LA, ORF 17070
Histrelin acetate, sold under the brand names Vantas and Supprelin LA among others, is a nonapeptide analogue of gonadotropin-releasing hormone (GnRH) with added potency. When present in the bloodstream, it acts on particular cells of the pituitary gland called gonadotropes. Histrelin stimulates these cells to release hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.
Histrelin is used to treat hormone-sensitive cancers of the prostate in men and uterine fibroids in women. En outre, histrelin has been proven to be highly effective in treating central precocious puberty in children.
It is available as a daily intramuscular injection.
Histrelin is also available in a 12-month subcutaneous implant (Vantas) for the palliative treatment of advanced prostate cancer, since 2005 in the US, and since Jan 2010 in the UK.
A 12-month subcutaneous implant (Supprelin LA) for central precocious puberty (CPP) was approved on May 3, 2007 by the U.S. Food and Drug Administration.
Histrelin can be part of the primary care protocol in transgender children/youth, which is an off-label use in the USA and the UK,and is used in suppressing cis-sex puberty, until the patient is ready to begin cross-sex hormonal therapy. It is also sometimes prescribed to transgender adults who benefit from having their sex hormone production halted.
